While transsphenoidal surgical resection is regarded as the first-line treatment for most secretory pituitary tumors, the recommended treatment for patients harboring prolactin-secreting pituitary adenomas involves dopamine agonists, aimed at reducing serum prolactin levels, decreasing tumor size, and restoring gonadal function [3,9]. This evidence concerns the gene PRL and pituitary tumor.